BeiGene Announces Authorisation of BRUKINSA (zanubrutinib) from the United Kingdom s MHRA for the Treatment of Adults with Waldenström s Macroglobulinemia in Great Britain streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Authorisation is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the United Kingdom (UK) Medicines and Healthcare